Cullinan Therapeutics (CGEM) Long-Term Investments (2021 - 2026)

Cullinan Therapeutics' Long-Term Investments history runs 6 years deep, the most recent figure standing at $38.5 million for Q1 2026.

• On a quarterly basis, Long-Term Investments fell 85.16% year-over-year to $38.5 million in Q1 2026; TTM through Mar 2026 was $38.5 million, a 85.16% decrease from a year earlier, with the FY2025 full-year figure at $58.3 million, down 71.5% from the prior year.
• Long-Term Investments eased to $38.5 million in Q1 2026 per CGEM's latest filing, from $58.3 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $259.4 million in Q1 2025 and bottomed at $13.5 million in Q3 2023.
• The 5-year median for Long-Term Investments is $69.6 million (2022), against an average of $99.6 million.
• Across the five-year window, Long-Term Investments jumped 328.03% in 2024 and sank 85.16% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $80.9 million in 2022, then plunged by 83.25% to $13.5 million in 2023, then soared by 1409.34% to $204.4 million in 2024, then plunged by 71.5% to $58.3 million in 2025, then slumped by 33.93% to $38.5 million in 2026.
• Per Business Quant, the three latest CGEM Long-Term Investments figures stand at $38.5 million (Q1 2026), $58.3 million (Q4 2025), and $140.0 million (Q3 2025).